Most people living with epilepsy are not just managing seizures. They are managing fatigue, mental fog, dizziness and drowsiness that come bundled with the medications meant to help them. That trade-off has been the quiet frustration of the epilepsy field for decades, and it is exactly the gap that a small-cap biotech called Biohaven Ltd. (NYSE: BHVN) is now trying to close.
Biohaven published new clinical data for its experimental epilepsy drug opakalim, a selective activator of Kv7.2/7.3 potassium channels in the brain. The mechanisms behind that name are complex, but the basic idea is straightforward: these channels act like a dimmer switch on nerve activity. When they work properly, they reduce the runaway electrical signaling that causes seizures. What makes opakalim notable is that it activates these channels with unusual precision, avoiding receptors that competing drugs also trigger and that appear to be responsible for many of the side effects patients find so debilitating.
The new data came from a randomized, placebo-controlled trial in patients with idiopathic generalized epilepsy, a form of the condition where seizure activity originates across the entire brain. Patients taking opakalim 75 mg once daily went a median of 141 days before experiencing a second generalized tonic-clonic seizure. Those on placebo reached that same point in just 47 days, representing a roughly threefold difference in how long patients stayed seizure-free. Among opakalim-treated subjects, 20% completed the full 24-week study period without any second seizure at all. None of the placebo patients managed that. One important caveat: the trial was closed before reaching its pre-specified enrollment target due to recruitment challenges and internal portfolio decisions, and formal statistical testing was not conducted. The signals are encouraging, but the company acknowledges the data is exploratory rather than definitive.
What arguably stands out even more than the efficacy numbers is the tolerability profile. In the opakalim group, there were zero reported cases of somnolence, dizziness, fatigue or memory impairment, the four side effects that plague virtually every approved anti-seizure medication currently on the market. For context, a competing investigational Kv7 activator, azetukalner, reported dizziness in 25% of patients, somnolence in 17%, memory impairment in 11%, and falls in 15% in its long-term open-label extension study. Opakalim reported dizziness in just 5% of patients in its own open-label focal epilepsy extension, where 54% of participants also achieved at least a 50% reduction in seizure frequency over any consecutive six months of treatment compared to their pre-treatment baseline.
The drug has now been studied in more than 1,000 subjects across multiple trials. Biohaven is currently running two pivotal Phase 2/3 studies in refractory focal epilepsy, with top-line results from the first of those trials expected in the second half of 2026. That readout is the next major test for the program. If it confirms what the earlier-stage data suggests, the company will have a compelling package to take toward regulatory review in a market that researchers value at over $12 billion globally in 2026 and growing.
For investors, the setup has an asymmetric quality that is uncommon in small-cap biotech. With approximately $351 million in cash on hand and a market capitalization of roughly $1.45 billion, the company is trading at a modest premium to its cash position while carrying several late-stage programs. Beyond epilepsy, Biohaven has a pipeline that includes taldefgrobep for obesity, BHV-1300 for Graves’ disease, and BHV-1400 for IgA nephropathy, all built around proprietary drug discovery platforms. The stock has declined more than 38% over the past twelve months but recovered approximately 13% in just the last five days ahead of this data release.
The epilepsy field has seen promising drugs disappoint in pivotal trials before, and opakalim is not approved. The risk is real. The pivotal readout in the second half of this year will either validate the clinical story Biohaven has been building or raise hard questions about it. What the current data does establish is that the tolerability case is already unusually strong, and that is the kind of differentiation that, if it holds up, tends to matter a great deal once physicians are actually choosing between treatment options for patients who are already exhausted by the side effects of their current medications.Â
